CXCR4 and neoplasm: In a mouse GBM model, inhibition of CXCR4 with plerixafor (formerly known as AMD3100) prevented recruitment of bone marrow-derived cells (mainly CD11b+ cells), which together with irradiation (5x2Gy or 1x15Gy) prevented tumor recurrence [78], suggesting that these CD11b+ monocytes or their differentiated progeny, TAMs, supply signals for the formation of new vessels.